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The  present  study  deals  with  the  loading  of  silver  sulfadiazine  into  ordered  mesoporous  silica  material
by post-impregnation  method  and  its effect  on the  in  vitro  release  kinetics  and  antimicrobial  prop-
erty  of the drug.  The  formulated  SBA-15  silica  material  with rope-like  morphology  and  SBA-15-silver
sulfadiazine  (SBA-AgSD)  were  characterized  by  UV–visible  spectrophotometer,  small  and  wide-angle
powder  X-ray  diffraction  (PXRD),  ﬁeld  emission  scanning  electron  microscope  (FESEM)  and high  reso-
lution  transmission  electron  microscope  (HRTEM).  Thermo-gravimetric  analysis  of  SBA-AgSD  revealed
a  high  loading  amount  of  52.87%.  Nitrogen  adsorption–desorption  analysis  conﬁrmed  the  drug  entrap-
ment  into  host  material  by revealing  a  reduced  surface  area  (214  m2/g)  and  pore  diameter  (6.7  nm)  of
the  SBA-AgSD.  The  controlled  release  of silver  sulfadiazine  drug  from  the  mesoporous  silica  to  simulated
gastric,  intestinal  and  body  ﬂuids  was  evaluated.  The  Korsmeyer–Peppas  model  ﬁts  the  drug  release  data
with the  non-Fickian  diffusion  model  and  zero  order  kinetics  of SBA-AgSD.  The  antibacterial  performance
of  the  SBA-AgSD  was  evaluated  with  respect  to  Staphylococcus  aureus,  Bacillus  subtilis  and  Pseudomonas
aeruginosa.  The  controlled  drug  delivery  of  the SBA-AgSD  revealed  improved  antibacterial  activity,  thus
endorsing  its  applicability  in effective  wound  dressing.
©  2016  The  Ceramic  Society  of Japan  and  the Korean  Ceramic  Society.  Production  and hosting  by
Elsevier  B.V.  This  is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/. Introduction
Nowadays, mesoporous nanomaterials have gained lots of inter-
st as a drug carrier material due to their various beneﬁcial
roperties such as biocompatibility, ability to control the drug
elease rate, non-toxicity, etc. Recently, silica based ordered meso-
orous materials, commonly known as SBA-15, have provoked
pecial consideration in the pharmaceutical ﬁeld due to its unique
dvantages in many aspects such as biodegradability and biocom-
atibility, tunable pore size and structure, large surface areas and
ore volumes, controllable morphology and modiﬁable surfaces
ith desirable functional group, high chemical and thermal sta-
ilities, etc. [1,2]. The discovery and use of triblock copolymer
emplate give birth to a polymorphic SBA-15. It is quite easy to∗ Corresponding author. Tel.: +91 9813170944.
E-mail address: surender6561@gmail.com (S. Duhan).
Peer review under responsibility of The Ceramic Society of Japan and the Korean
eramic Society.
ttp://dx.doi.org/10.1016/j.jascer.2016.05.005
187-0764 © 2016 The Ceramic Society of Japan and the Korean Ceramic Society. Producti
icense (http://creativecommons.org/licenses/by-nc-nd/4.0/).licenses/by-nc-nd/4.0/).
control the surface area and pore volume of non-toxic SBA-15 in
the range of 600–1600 m2/g and 0.6–1.3 cm3/g, respectively [3–6],
which is highly required to control the drug release. The pure SBA-
15 provides silanol groups on the channel walls, which form a weak
intermolecular hydrogen bond with drugs and allow storage of high
amount of a drug and also able to extend the drug release cycle in a
sustained manner [7]. This polymorphic silica based ordered meso-
porous material (or SBA-15) shows its proﬁciency in control drug
delivery system due to its gate like scaffold nature in pure and in
functionalized form [8–11].
In human body, the outermost lipophilic epithelial layer or
skin is the ﬁrst and second line of defense which provides the
essential immunity. The presence of sebum and acidity (pH 3–5)
in skin inhibits bacterial growth. But due to the advancement of
technology and fast speed of life, most of the people suffer from
burns, wounds and other types of skin diseases. Therefore, in the
absence of this skin like swaddle, human body provides excel-
lent medium for the development and propagation of pathogenic
microorganisms. Thus, the development of innovative wound and
burn dressing advancement is in great demand [12,13]. It is well
on and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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nown that the silver and its compounds such as silver sulfadiazine
AgSD) are widely used in most of the skin complications because
f their peerless antimicrobial activity [14,15]. But, the AgSD shows
ytotoxicity and allergic reactions in clinical studies, which lead to
amper the healing progress of skin [16]. Therefore, a substitute
cenario is required to improve drug (AgSD) efﬁcacy. The antibac-
erial property requires a carrier which releases the drug for longer
ime but in a controlled manner. To fulﬁll this requirement, the
BA-15 can be used as an effective drug carrier which may  reduce
he drug cytotoxicity and enhance its efﬁcacy.
In the present study, an attempt has been made to load AgSD in
orous SBA-15 material in order to achieve the beneﬁcial properties
f both AgSD and SBA-15. The release kinetics of AgSD from the SBA-
5 to simulated gastric, intestinal and body ﬂuids was  studied. The
ntibacterial performance of the SBA-AgSD was also evaluated with
espect to Staphylococcus aureus,  Bacillus subtilis and P. aeruginosa.
n efﬁcient antibacterial agent in the form of AgSD loaded SBA-
5 has been developed. The SBA-AgSD proved its proﬁciency as an
xcellent and smart long range antibacterial ﬁghter against various
athogenic bacteria.
. Experimental
Reagents used for the synthesis of mesoporous materi-
ls: Pluronic P123 [ethylene oxide–propylene oxide–ethylene
xide (EO20PO70EO20), Mw = 5800], tetraethoxy orthosili-
ate [(C2H5O)4Si, TEOS] and HCl (35%) were procured from
igma–Aldrich.
Reagents used for the preparation of human simulated body
uid (SBF): phosphate buffer solution (PBS), HCl (hydrochloric
cid), NaCl (sodium chloride), KCl (potassium chloride), KH2PO4
potassium dihydrogen phosphate), NaOH (sodium hydroxide),
a2HPO4 (disodium hydrogen phosphate) were procured from
erck, India.
Silver sulfadiazine drug was generously gifted by Galentic
harma (India) Pvt. Ltd.
.1. Synthesis of SBA-15 matrix
The synthesis of mesoporous silica was performed in accor-
ance with our earlier reported work [17]. In a typical process,
nitially 2 g triblock copolymer, P123 was dissolved in 70 mL  dis-
illed water at 40 ◦C under high acidic conditions produced by the
ddition of 10 mL  HCl (2 M).  A clear solution was achieved after
 h of continuous mechanical stirring of the solution. Then, 4.8 mL
EOS was added to the above mentioned solution followed by con-
inuous stirring for another 24 h at 40 ◦C. Thereafter, the solution
as transferred to a Teﬂon lined stain-less steel autoclave and
ydrothermally treated at 100 ◦C for 24 h. After cooling down to
oom temperature, the solid products were ﬁltered, washed and
ried at 70 ◦C. Finally, the solid product was calcined at 600 ◦C with
 heating rate of 1 ◦C/min for 4 h in air to remove organic templates
nd to obtain mesoporous powder form SBA-15.
.2. Preparation of calibration curve of silver sulfadiazine in 0.1 N
Cl at max = 254 nm
Calibration curve of the drug silver sulfadiazine (AgSD) was
repared in 0.05% ammonia solution at max = 254 nm as shown
n Fig. 1. The AgSD of about 100 mg  was weighed and dissolved
n 1000 mL  0.05% ammonia solution to get a concentration of
00 g/mL. 2 mL  from this stock solution was further diluted to
0 mL  with 0.05% ammonia solution to obtain a concentration
f 20 g/mL. Serial dilutions of 2–20 g/mL were prepared using
.05% ammonia solution. A calibration curve was  obtained by
ecording the absorbance of each diluted solution at 280 nm in aConcentration  (μg/mL )
Fig. 1. Calibration curve of AgSD in 0.05% ammonia solution at max = 254 nm.
UV–visible double beam spectrophotometer. A regression equa-
tion between the absorbance (A) and concentration (C, g/mL) was
obtained: A = 0.009C + 0.007, R2 = 0.992, so that the concentration of
drug in solution can be obtained using Eq. (1):
C = A − 0.007
0.009
, in g/mL (1)
2.3. Drug loading
The loading of AgSD was achieved by post-impregnation
method. The AgSD (200 mg)  was dissolved in 20 mL  of 0.1 N HCl
solutions and soaked with SBA-15 (250 mg)  under continuous stir-
ring for 12 h at 500 rpm. The pellet obtained after centrifugation
(15,000 rpm at 4 ◦C for 1 h) was  dried and preserved under vacuum
at room temperature for further characterization.
The drug entrapment (EE%) in mg/mL  and loading efﬁciency (PE)
in mg/g was  calculated by UV–visible spectroscopy at 254 nm using
respective blank following Eqs. (2) and (3).
EE% = (Ci − Cf)
Ci
× 100 (2)
PE =
(Ci − Cf)
W
× V (3)
where PE is the amount of drug absorbed into the matrix (mg/g;
mg azathioprine per gram SBA-15), Ci and Cf (mg) are initial and
ﬁnal concentrations of the azathioprine in the reaction solution
(mg/mL), respectively, V is the volume of the reaction solution (mL),
and W is the weight of the SBA-15 (g).
2.4. In vitro drug release measurements
The drug release behavior of the loaded samples were inves-
tigated in simulated gastric ﬂuid (SGF), simulated intestinal ﬂuid
(SIF) and simulated body ﬂuid (SBF) at different pH of about 1.2, 6.8
and 7.2, respectively. To study the release of AgSD from SBA-15, the
loaded powders were immersed in different ﬂuids under magnetic
stirring in a dialysis membrane. The AgSD loaded SBA-15; equiv-
alent to 15 mg  of the drug was transferred into the dialysis bag.
Sample aliquots (5 mL) were withdrawn at speciﬁc time intervals
and were subsequently replenished with fresh dissolution medium.
Hence, a corrected method was  employed to determine the real
content of AgSD released from the SBA-15 material, using Eq. (4)Ct−corrected = Ct +
v
V
t−1∑
0
Ct (4)
2  Ceramic Societies 4 (2016) 282–288
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Table 1
The drug entrapment (EE%) efﬁciency, loading efﬁciency (PE) and chemical analysis
results of SBA-AgSD.
Sample name UV–visible spectrophotometry TGA (%)
(EE%) (PE%)
SBA-15-silver sulfadiazine 70.67 52.67 52.87 ± 1.95
(a)
(c)
(b)84 S. Jangra et al. / Journal of Asian
here Ct−corrected is the real concentration of azathioprine released
t time t, Ct is the content measured on UV–visible spectrometer
f release ﬂuid sampled at time t, v the sampled volume taken at
peciﬁc time interval, and V is the total volume of release ﬂuid.
.5. Antimicrobial activity
Three bacterial cultures such as S. aureus MTCC 2901, B. sub-
ilis MTCC 2616, and P. aeruginosa MTCC 424 were procured from
icrobial Type Culture Collection, IMTECH, Chandigarh and Culture
ollection Laboratory, Department of Bio and Nano Technology, G.J.
niversity of Science Technology, Hisar. The stoke cultures were
aintained on nutrient agar slants at 4 ◦C in a refrigerator by regular
ransfer.
.5.1. Medium used for bacterial culture
Nutrient broth medium: ingredients used: peptone (10 g/l), beef
xtract (10 g/l), sodium chloride (5 g/l) and agar @ 2% were used.
.5.2. Inoculums preparation of bacteria
About 20 mL  of sterilized nutrient agar medium was  transferred
o sterilize Petri plates with the help of inoculating loop to obtain
resh growth. The Petri plates containing bacterial cultures were
ncubated at 37 ◦C for 12 h and bacterial growth was observed.
acteria containing loop was transferred to 50 mL  sterilized nutri-
nt broth medium and incubated on an incubator shaker for 12 h.
.5.3. Agar well diffusion test
The nutrient agar medium was poured in sterilized Petri plates
nd allowed to solidify at room temperature. About 60 L of the
acteria cultures (S. aureus,  B. subtilis and P. aeruginosa) from
he fresh culture were spread over the media with the help of
 spreader. Then the wells (5 mm)  were punched in the medium
ith the help of sterilized cork borer. The wells were labeled and
0 L nanoparticles suspension (drug loaded SBA-15) and pure
amples (300 mM,  silver sulfadiazine drug) were transferred to the
espective wells with the help of a micropipette. The Petri plates
ere sealed and incubated in a biochemical oxygen demand (BOD)
ncubator for 12 h. The zone of inhibition was observed and the
iameters of zones were measured by a scale and divider.
.6. Characterization
The content of AgSD in SBA-AgSD material was determined
sing UV–visible spectrophotometry (Shimadzu UV-2450, Mil-
on Keynes, UK) [18]. The TGA experiments were performed
o determine the drug loading amount on a SDT Instrument
Q-600 DSC–TGA). Powder small and wide-angle X-ray diffraction
PXRD) patterns were obtained on a Bruker D8 advance diffactome-
er using Cu K as target material ( = 0.15418 nm) to determine
he crystallinity of the samples. For small-angle analysis, signal
as recorded from 0.5◦ to 4◦ with a scanning step of 0.01◦ and
 time per step of 10 s. But, for wide-angle analysis, signal was
ecorded from 20◦ to 70◦ with a scanning step of 0.05◦ and a
ime per step of 2 s. Morphology of pure SBA-15 and SBA-AgSD
as characterized by ﬁeld emission scanning electron microscopeFESEM, FEI QUANTA 200F) and high resolution transmission elec-
ron microscope (HRTEM, TECNAI G20) operated at an accelerating
oltage of 200 kV. At a temperature of −196 ◦C, a Micrometrics
ri-Star analyzer was used to obtain N2 adsorption–desorption
sotherms. Using the isotherms speciﬁc surface area and pore
hannel structural parameter were calculated by following BET
Brunner–Emmett–Teller) method.Fig. 2. Thermo-gravimetric analysis (TGA) of (a) SBA-15, (b) AgSD and (c) SBA-AgSD.
3. Results and discussion
3.1. Drug loading efﬁciency
The spectrophotometry was used for calculation of AgSD in SBA-
AgSD. The drug entrapment (EE%) efﬁciency, loading efﬁciency (PE)
and chemical analysis results of AgSD in SBA-AgSD are summarized
in Table 1. Drug loading efﬁciency was further conﬁrmed using TGA.
The TGA thermograms of SBA-15, AgSD and SBA-AgSD are shown
in Fig. 2. The TGA proﬁle of SBA-15 shows a small mass loss of
about 10% up to 800 ◦C. The initial mass loss of SBA-15 up to 200 ◦C
attributed to thermos-desorption of water from mesoporous struc-
ture of SBA-15. Afterward, the SBA-15 showed very small mass loss
on heating up to 800 ◦C, which may  be attributed to the condensa-
tion and dehydroxylation of the silanol groups of the material. In
case of the AgSD, the mass loss observed between the temperatures
250–365 ◦C and 366–800 ◦C is attributed to the drug decomposition
in two steps. But, the total mass loss detected for the SBA-AgSD in
the temperature range of 25–800 ◦C is about 61.87% and total mass
loss for SBA-15 is about 9% which corresponds to the drug loading
of 52.87% in the SBA-15 matrix.
3.2. Small and wide-angle X-ray diffraction
The low angle XRD (LAXRD) spectra for mesoporous silica (or
SBA-15) given in Fig. 3 show three well resolved peaks in 2 range of
0.5–2.0◦. The diffraction peaks at 2 = 0.86◦, 1.53◦ and 1.61◦ which
can be indexed to (1 0 0), (1 1 0) and (2 0 0) respectively, in XRD
pattern corresponds to hexagonal p6mm space group for meso-
porous silica material. A peak shrinkage and rightwards d-shifting
along (1 0 0) direction was observed in case of the SBA-AgSD due to
pore ﬁlling of mesoporous framework. Moreover, the small angle
X-ray diffraction pattern of SBA-AgSD material indicates signiﬁ-
cant decline in the intensity of the diffraction peaks with d-spacing
value. The decrease in intensity should be due to the pore ﬁlling
of mesoporous SBA-15 which can lessen the scattering contrast
S. Jangra et al. / Journal of Asian Ceram
(a)
(b)
Fig. 3. Small-angle X-ray diffraction patterns of (a) SBA-15 and (b) SBA-AgSD.
(a)
(b)
(c)
F
A
b
a
a
a
listed in Table 2 depict a systematic decrease in surface area withig. 4. Wide-angle X-ray diffraction patterns of (a) SBA-15, (b) AgSD and (c) SBA-
gSD.
etween the pores and side walls of SBA-15. However, the wide-
ngle XRD patterns (2  = 20–50◦) of AgSD, SBA-15 and SBA-AgSD
re shown in Fig. 4. The curve of AgSD shows two  major peaks
t 2 = 22◦ and 27◦ along with other characteristics peaks which
Fig. 5. HRTEM images of (a) SBic Societies 4 (2016) 282–288 285
indicates its crystalline nature. It is well known that SBA-15 is
amorphous in nature; that is why  it is showing no diffraction peaks.
The XRD pattern of SBA-AgSD shows only one sharp peak that may
be due to detection of collective AgSD by the powder XRD on the
outer surface of the porous silica material. Based on the absence of
the remaining peaks it may  be inferred that the drug is homoge-
neously dispersed inside the SBA-15 pore channels.
3.3. HRTEM and FESEM analysis
The HRTEM images in Fig. 5(a) and (b) show hexagonal pores
with long range pore arrangement which conﬁrms the 2D p6mm
regular hexagonal mesostructure of SBA-15 and SBA-AgSD. The
encapsulation of AgSD drug into the channels of SBA-15 does not
change its hexagonal mesoporous channel structure. The drug is
homogeneously dispersed in the mesoporous framework due to the
presence of uniform cylindrical pores of equal widths to effectively
accommodate the drug. Silver sulfadiazine and silica were simulta-
neously introduced into the reaction system during the initial phase
of prolonged stirring for the homogeneous distribution of the drug.
The average distance between the adjacent centers of hexagonal
pores for pure mesoporous silica estimated from high magniﬁca-
tion HRTEM images (not shown here) is found to be 12.6 nm. The
average thickness of the wall and the pore diameter acquired from
the high magniﬁcation HRTEM images are around 4 nm and 8.5 nm,
respectively which is quite consistent with the results obtained
from N2 adsorption/desorption analysis.
FESEM micrographs of SBA-15 and SBA-AgSD shown in
Fig. 6(a) and (b) reveal long rod-like domains agglomerated to
wheat-like microstructures. This type of structure comprises large
ﬁbrous structures varying from 3 to 10 m in length and 2 to 5 m
in diameter. The ﬁbrous structure consists of a large number of
ﬁbers which are made of a small rod-like particles of 0.3–3.5 m
in length and 0.4–0.7 m in diameter. The FESEM microstructure
shows the change in morphology of mesoporous silica due to the
presence of AgSD. Weakly trapezoidal, wheat grain-like particles
are observed without the AgSD, while in presence of the AgSD the
particles became smaller.
3.4. N2 adsorption/desorption isotherms
The low temperature nitrogen adsorption–desorption
isotherms of AgSD and SBA-AgSD exhibit type IV characteris-
tics curves and H1 type broad hysteresis loop which unerringly
matches with the International Union of Pure and Applied Chem-
istry classiﬁcation of mesoporous materials indicating a uniform
cylindrical geometry as shown in Fig. 7. Physicochemical propertiesloading of AgSD drug; however due to loading of drug in meso-
porous silica the shape of type IV curves with H1 hysteresis loop
was well maintained. The BET analysis reveals a decrease in pore
A-15 and (b) SBA-AgSD.
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Fig. 6. FESEM micrographs of (a) SBA-15 and (b) SBA-AgSD.
Table 2
Illustrates the pore parameters such as average pore diameter, BET speciﬁc surface area, pore volume, etc. of the pure SBA-15 and SBA-AgSD.
Sample name SBET (m2/g) VP (cm3/g) DP (nm) DW (nm) a0 (nm) d1 0 0-Spacing
SBA-15 637 0.96 9.5 2.64 11.40 9.90
SBA-15-silver sulfadiazine 214 0.27 6.7 0.45 11.01 9.50
d1 0  0: d-spacing.
a0: unit cell parameter [a0 = 2 × d1 0 0/
√
3].
DP: pore size.
VP: pore volume.
DW: pore wall thickness [DW = a0 − DP].
SBET: total surface area of SBA-15 and SBA-15-silver sulfadiazine composite.
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tig. 7. Low temperature nitrogen adsorption–desorption isotherms of (a) SBA-15
nd  (b) SBA-AgSD.
iameter of SBA-AgSD with increasing drug % due to the hindrance
aused by partially ﬁlled pores in the path of forthcoming AgSD
rug. This continuous blockage of pores causes the broadening
f the walls of the SBA-AgSD suggesting that the AgSD drug has
een conﬁned inside the pore channels of mesoporous silica. The
peciﬁc surface area, pore size, pore volume, pore wall thickness,
nit cell parameter and d-spacing details of SBA-15 and SBA-AgSD
re summarized in Table 2. From Table 2, it can be clearly observed
hat all the parameters of the pure SBA-15 and SBA-AgSD such as
peciﬁc surface area, pore volume and pore diameter, pore wall
iameter, unit cell parameter and d-spacing are decreased. This
esult reveals that after the loading of AgSD, the pore channels
f SBA-15 are either partially ﬁlled or completely jammed. This
onﬁrms that the molecules of AgSD are successfully included in
he SBA-15 channels.Fig. 8. In vitro release proﬁle of AgSD from SBA-AgSD in different ﬂuids: (A) SIF (),
(B)  SGF (©), and (C) SBF ().
3.5. In vitro release
The drug loading ability of mesoporous SBA-15 is also illustrated
in Table 1. In vitro cumulative release proﬁles of AgSD drug from the
SBA-AgSD in different ﬂuids (simulated gastric ﬂuid (SGF), pH = 1.2,
simulated intestinal ﬂuid (SIF), pH = 6.8 and simulated body ﬂuid
(SBF), pH = 7.2) are shown in Fig. 8. Sustained release of AgSD drug
in all ﬂuids ﬁnished in 72 h. In the ﬁrst 48 h, the sustained drug
release rate was  fast and that may  be due to adsorption of the drug
on surface of the composite material. But, after 72 h, basically the
sustained drug release completed. Basically, the drug release from
the mesoporous structure of SBA-15 follows two routes: one is the
solvent diffusion into the pores to dissolve the AgSD drug and sec-
ond one is the solvated drug diffusion to the outer part of the pores.
For drug loaded SBA-15 drenched in the release ﬂuid along with
S. Jangra et al. / Journal of Asian Ceramic Societies 4 (2016) 282–288 287
Fig. 9. Antibacterial activity of (1) AgSD, (2) SBA-AgSD and (3) SBA-15 against (a) S. aureus, (b) P. aeruginosa and (c) B. subtilis.
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dFig. 10. Relative antibacterial ac
H near to neutral pH, which is different from high proton con-
itions because of the drug dissociation. The slow release rate of
gSD beneﬁts the human body by prolonged use of drug and reduc-
ng unnecessary waste of the drug and also enhancing cycle time
f drug in human body or in other words the therapeutic effect of
reatment is enhanced. Thus, the dissolution rate of AgSD in the
BA-AgSD is controlled by pH of the solution.
.6. Drug release mechanism
To inspect the AgSD drug release mechanism from SBA-15
nto simulated ﬂuids, a non-linear Korsmeyer–Peppas model was
pplied. The result achieved with the Korsmeyer–Peppas model
ndicates decent regression coefﬁcient R2 ranging from 0.971 to
.998 in body ﬂuids. The AgSD drug releases into the different simu-
ated ﬂuids by the diffusion action from mesoporous silica channels.
he silver sulfadiazine drug gradually dissolves into the simu-
ated ﬂuid and then the drug slowly diffuses from the mesoporous
ilica capillary channels in accordance with a dissolution-ﬁlling
pproach. A complete equation to explain drug release kinetics is
entioned below [18]:
Mt
M∞
= ktn (5)
hen n < 0.5 then the drug release mechanism follows Fickian
iffusion model (Peppas, 1985) and if 0.5 < n < 0.89 then release
echanism follows an anomalous diffusion model [19]. If n = 0.5
hen the release mechanism follows Higuchi kinetic model [20] and
f 0.89 < n < 1 then the release mechanism follows zero-order kinetic
odel. Mt and M∞ represent the cumulative mass of drug released
t time t and at inﬁnite time respectively, where k is a characteristic
inetic constant of drug-carrier scheme and n is an exponent which
eﬁnes the release mechanism. The exponent n (which deﬁnes theof SBA-15, AgSD and SBA-AgSD.
release mechanism) has value in the range of 0.532–0.989 corre-
sponding to the non-Fickian diffusion or anomalous release and
zero-order kinetics. Therefore, these results propose a clear effect
of the pore size of SBA-AgSD on diffusion behavior.
3.7. Antimicrobial activity
The antibacterial performances of SBA-15, AgSD and SBA-AgSD
are shown in Fig. 9. The inhibitory power of tested samples on the
growth of the bacteria was  resolved by measuring diameter of inhi-
bition zone. The zones of inhibition of the SBA-15, AgSD drug and
SBA-AgSD against S. aureus, B. subtilis and P. aeruginosa are clearly
shown in Fig. 10. From these results, it can be inferred that the SBA-
AgSD has better ﬁghting ability against severe pathogenic bacteria
compared to the AgSD drug.
4. Conclusions
SBA-15 mesoporous material was formulated and applied
to load silver sulfadiazine drug by post-impregnation method.
UV–visible spectrophotometry revealed the maximum drug load-
ing efﬁciency of 52.67% and encapsulated efﬁciency of 70.67%. The
drug loading efﬁciency of 54.72% was  observed by TGA analysis.
Powder XRD and electron microscopy revealed the homogeneous
dispersion of the AgSD drug inside the SBA-15 pore channels.
Nitrogen adsorption–desorption isotherms conﬁrmed the success-
ful encapsulation of the AgSD drug into the channels of SBA-15.
Sustained release of AgSD drug from the SBA-AgSD in all three sim-
ulated ﬂuids basically ﬁnished in 72 h with a release amount greater
than 95%. The AgSD loaded SBA-15 presented better antimicrobial
properties compared to that of the drug itself. The controlled drug
release properties and enhanced antimicrobial properties of SBA-
AgSD will be lucrative in order to produce a long term antibacterial
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